Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. Zeuzem S, et al. Among authors: schalm sw. J Hepatol. 2005 Aug;43(2):250-7. doi: 10.1016/j.jhep.2005.05.016. J Hepatol. 2005. PMID: 16082736 Clinical Trial.
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Among authors: schalm sw. Hepatology. 2006 Dec;44(6):1617-25. doi: 10.1002/hep.21407. Hepatology. 2006. PMID: 17133471 Clinical Trial.
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups. Askarieh G, et al. Among authors: schalm sw. Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509. Hepatology. 2010. PMID: 20186843 Clinical Trial.
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K; DITTO-HCV Study Group. Westin J, et al. Among authors: schalm sw. J Viral Hepat. 2007 Jan;14(1):29-35. doi: 10.1111/j.1365-2893.2006.00777.x. J Viral Hepat. 2007. PMID: 17212641 Clinical Trial.
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Orlent H, et al. Among authors: schalm sw. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015. Epub 2006 Jun 30. J Hepatol. 2006. PMID: 16905220 Clinical Trial.
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Romero AI, et al. Among authors: schalm sw. J Infect Dis. 2006 Oct 1;194(7):895-903. doi: 10.1086/507307. Epub 2006 Aug 29. J Infect Dis. 2006. PMID: 16960776 Clinical Trial.
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Among authors: schalm sw. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
461 results